Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Ovarian Cancer (6 results)

Printer Friendly Page 1 through 6 of 6
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor

Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.

Clinicaltrials.gov identifier: NCT06065059
More info
Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

Clinicaltrials.gov identifier: NCT04673448
More info
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Treatment
Treatment study for people with advanced solid tumors

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

Clinicaltrials.gov identifier: NCT04550494
More info
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Treatment
Recurrent ovarian cancer

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

Clinicaltrials.gov identifier: NCT03462342
More info
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Clinicaltrials.gov identifier: NCT05252390
More info
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

Clinicaltrials.gov identifier: NCT04644068
More info
Additional Results on Clinicaltrials.gov Treatment + Ovarian Cancer + parp
22 results
Clinical Trial Official Title
NCT04673448 Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT05797168 Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
NCT05071937 ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NCT05942300 CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
NCT03462342 Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
NCT06161493 ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
NCT06120972 Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT03579316 Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT04633239 Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT03574779 A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
NCT04550494 Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04703920 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT05700669 Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT04606914 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT05887609 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
NCT05554328 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05417594 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Research Search Tool Sponsored By: